Therapy with Antibody to Tumor Necrosis Factor Against Endotoxin Shock in Rabbits

Overview

Journal J Anesth

Specialty Anesthesiology

Date 2013 Apr 10

PMID 23568118

Authors

K Ishizaki

Y Youda

D M Yoon

K Arai

T Fujita

Affiliations

Soon will be listed here.

Abstract

The purpose of this study was to determine the efficacy of treatment with anti-tumor necrosis factor (TNF) antibody in preventing the deleterious effects of endotoxin. Polyclonal anti-TNF antibody was produced by immunizing rabbits. Experiments were carried out on 16 rabbits intravenously infused with the lethal dose of lipopolysaccharide (LPS). Pretreatment with anti-TNF antibody resulted in protection from the development of hypotension and metabolic acidosis. The serum TNF level was significantly depressed in the antibody-pretreated group. Eighty-eight percent in the anti-TNF antibody-pretreated rabbits survived more than 48 h, whereas none of the rabbits who were given LPS alone survived over 24 h (LPS group). Prominent histopathological changes in the liver and kidney were evident in the LPS group. In contrast, pathologic changes in the tissue from the anti-TNF antibody group were considerably less prominent. These results support the idea that TNF plays a central role in mediating the pathophysiologic changes during endotoxin shock.

References

Dinarello C, Cannon J, Wolff S, Bernheim H, Beutler B, Cerami A . Tumor necrosis factor (cachectin) is an endogenous pyrogen and induces production of interleukin 1. J Exp Med. 1986; 163(6):1433-50. PMC: 2188124. DOI: 10.1084/jem.163.6.1433. View

Ertel W, Morrison M, Wang P, Ba Z, Ayala A, Chaudry I . The complex pattern of cytokines in sepsis. Association between prostaglandins, cachectin, and interleukins. Ann Surg. 1991; 214(2):141-8. PMC: 1358513. DOI: 10.1097/00000658-199108000-00008. View

Kreger B, Craven D, McCabe W . Gram-negative bacteremia. IV. Re-evaluation of clinical features and treatment in 612 patients. Am J Med. 1980; 68(3):344-55. DOI: 10.1016/0002-9343(80)90102-3. View

Fong Y, Tracey K, Moldawer L, Hesse D, Manogue K, KENNEY J . Antibodies to cachectin/tumor necrosis factor reduce interleukin 1 beta and interleukin 6 appearance during lethal bacteremia. J Exp Med. 1989; 170(5):1627-33. PMC: 2189514. DOI: 10.1084/jem.170.5.1627. View

Hinshaw L, Chang A, Lee P, Taylor Jr F, Murray C, Peer G . Survival of primates in LD100 septic shock following therapy with antibody to tumor necrosis factor (TNF alpha). Circ Shock. 1990; 30(3):279-92. View

Tracey K, Beutler B, Lowry S, Merryweather J, Wolpe S, Milsark I . Shock and tissue injury induced by recombinant human cachectin. Science. 1986; 234(4775):470-4. DOI: 10.1126/science.3764421. View

Beutler B, Cerami A . Cachectin and tumour necrosis factor as two sides of the same biological coin. Nature. 1986; 320(6063):584-8. DOI: 10.1038/320584a0. View

Remick D, Kunkel R, Larrick J, Kunkel S . Acute in vivo effects of human recombinant tumor necrosis factor. Lab Invest. 1987; 56(6):583-90. View

Neilson I, Neilson K, Yunis E, Rowe M . Failure of tumor necrosis factor to produce hypotensive shock in the absence of endotoxin. Surgery. 1989; 106(2):439-43. View

10.

Fong Y, Moldawer L, Marano M, Wei H, Barber A, Manogue K . Cachectin/TNF or IL-1 alpha induces cachexia with redistribution of body proteins. Am J Physiol. 1989; 256(3 Pt 2):R659-65. DOI: 10.1152/ajpregu.1989.256.3.R659. View

11.

Wyler F, NEUTZE J, Rudolph A . Effects of endotoxin on distribution of cardiac output in unanesthetized rabbits. Am J Physiol. 1970; 219(1):246-51. DOI: 10.1152/ajplegacy.1970.219.1.246. View

12.

Bottoms G, Johnson M, Ward D, Fessler J, Lamar C, Turek J . Release of eicosanoids from white blood cells, platelets, smooth muscle cells, and endothelial cells in response to endotoxin and A23187. Circ Shock. 1986; 20(1):25-34. View

13.

Waage A, Brandtzaeg P, Halstensen A, Kierulf P, Espevik T . The complex pattern of cytokines in serum from patients with meningococcal septic shock. Association between interleukin 6, interleukin 1, and fatal outcome. J Exp Med. 1989; 169(1):333-8. PMC: 2189201. DOI: 10.1084/jem.169.1.333. View

14.

CARSWELL E, Old L, Kassel R, Green S, Fiore N, Williamson B . An endotoxin-induced serum factor that causes necrosis of tumors. Proc Natl Acad Sci U S A. 1975; 72(9):3666-70. PMC: 433057. DOI: 10.1073/pnas.72.9.3666. View

15.

Moore Jr F, Socher S, Davis C . Tumor necrosis factor and endotoxin can cause neutrophil activation through separate pathways. Arch Surg. 1991; 126(1):70-3. DOI: 10.1001/archsurg.1991.01410250076012. View

16.

Parsonnet J, Gillis Z . Production of tumor necrosis factor by human monocytes in response to toxic-shock-syndrome toxin-1. J Infect Dis. 1988; 158(5):1026-33. DOI: 10.1093/infdis/158.5.1026. View

17.

Debets J, van der Linden C, Spronken I, Buurman W . T cell-mediated production of tumour necrosis factor-alpha by monocytes. Scand J Immunol. 1988; 27(5):601-8. DOI: 10.1111/j.1365-3083.1988.tb02388.x. View

18.

Evans D, Jacobs D, Revhaug A, Wilmore D . The effects of tumor necrosis factor and their selective inhibition by ibuprofen. Ann Surg. 1989; 209(3):312-21. PMC: 1493947. DOI: 10.1097/00000658-198903000-00011. View

19.

Beutler B, Greenwald D, Hulmes J, Chang M, Pan Y, Mathison J . Identity of tumour necrosis factor and the macrophage-secreted factor cachectin. Nature. 1985; 316(6028):552-4. DOI: 10.1038/316552a0. View

20.

Ziegler E, Fisher Jr C, Sprung C, Straube R, Sadoff J, Foulke G . Treatment of gram-negative bacteremia and septic shock with HA-1A human monoclonal antibody against endotoxin. A randomized, double-blind, placebo-controlled trial. The HA-1A Sepsis Study Group. N Engl J Med. 1991; 324(7):429-36. DOI: 10.1056/NEJM199102143240701. View